Nature Communications (Feb 2020)

Immunoproteasome expression is associated with better prognosis and response to checkpoint therapies in melanoma

  • Shelly Kalaora,
  • Joo Sang Lee,
  • Eilon Barnea,
  • Ronen Levy,
  • Polina Greenberg,
  • Michal Alon,
  • Gal Yagel,
  • Gitit Bar Eli,
  • Roni Oren,
  • Aviyah Peri,
  • Sushant Patkar,
  • Lital Bitton,
  • Steven A. Rosenberg,
  • Michal Lotem,
  • Yishai Levin,
  • Arie Admon,
  • Eytan Ruppin,
  • Yardena Samuels

DOI
https://doi.org/10.1038/s41467-020-14639-9
Journal volume & issue
Vol. 11, no. 1
pp. 1 – 12

Abstract

Read online

The response to immunotherapy of melanoma patients is heterogeneous. Here, the authors demonstrate that a high expression of the two major components of the immunoproteasome, PSMB8 and PSMB9, modulates the production of HLA peptides and it is predictive of better survival and improved response to immune-checkpoint inhibitors of melanoma patients.